Search
Menu
Home
HTB
2020
March
12
12 March 2020
Contents
Editorial
HTB 12 March 2020 now online
HTB survey 2020 – please help with feedback
Special reports
Fit for purpose: antiretroviral treatment optimisation March 2020
HIV pipeline 2020: new drugs in development – March 2020
Conference reports
Conference on Retroviruses and Opportunistic Infections (CROI 2020)
CROI 2020: Special session on COVID-19
Monthly islatravir for PEP and PrEP: 12 pills a year could cover unmet need for HIV prevention in billions of people globally
Long-acting cabotegravir and rilpivirine injections support two-monthly dosing
Safety and PK of bNAb elipovimab (GS-9722) support two-weekly dosing
First results with long-acting capsid inhibitor GS-6207: oral and subcutaneous formulations for use in naïve and multidrug resistance
Predicted diabetes risk with first-line ART regimens: results from the ADVANCE trial
Postpartum weight gain is higher with dolutegravir- compared with efavirenz-based ART among African women
London patient is second person to be cured of HIV from allogeneic stem-cell transplant
The London Patient tells his story as second person cured of HIV
Treatment access
Dolutegravir/lamivudine FDC recommended by NHS England
PDFs
12 March 2020 vol 21 no 3
HTB RSS
Early access
US government has altered more than 100 scientific databases since 20 January
5 July 2025
All early access reports
Current issues
July 2025
June 2025
May 2025
Back issues
Special report
Why the new HIV PrEP guidelines from the UK are so exciting (2025)
2 July 2025
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate